188
Omalizumab in children with allergic
asthma
1
LanierB,
etal
.
JAllergyClinImmunol
2009;124:1210–6;
2
KulusM,
etal
.
CurrMedResOpin
2010;26:1285–93;
3
MilgromH,
etal
.
Pediatrics
2001;108:e36;
4
BusseW,
etal
.
NE
n
glJMed
2011;364:1005–15.
IA05
1
Moderate‐to‐severe
Severe
IA05-EU
2
Moderate‐to‐severe
(well controlled)
N=334
Steroid sparing
28 Weeks
010
3
ICATA
4
N=246
Exacerbations
52 Weeks
N=628
Exacerbations
52 Weeks
Omalizumab reduced
seasonal exacerbations
in inner city children and
adolescents with persistent
asthma over 60 weeks
0,31
0
0,43
0,46
0
0,1
0,2
0,3
0,4
0,5
Baseline
28 weeks
p=0.004
Rescue medication use reduced
during omalizumab treatment
Median salbutamol use (puffs/day)
Omalizumab (n=225)
Placebo (n=109)
010
Milgrom H,
et al. Pediatrics
2001;108:e36.
Simposium
